Authors
Loading...
Analysis identifies eIF4A as a target in mtNPM1 AML, suggesting new treatment strategies for resistant cells.
Mill et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: